Building parity between brand and generic peptide products: Regulatory and scientific considerations for quality of synthetic peptides.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  International journal of pharmaceutics

• Publication date

  2017-02-25

• Fields of study

  Medicine, Chemistry, Computer Science

• Identifiers
  DOI 10.1016/j.ijpharm.2016.12.051PMID 28027918
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peptide and Protein Drug Delivery

  2024cited by this paper
• Insoluble protein assemblies characterized by fourier transform infrared spectroscopy.

  2015cited by this paper
• Chemical degradation of proteins in the solid state with a focus on photochemical reactions.

  2015cited by this paper
• Detection of Innate Immune Response Modulating Impurities in Therapeutic Proteins

  2015cited by this paper
• Extractables and leachables considerations for prefilled syringes

  2014cited by this paper
• Related impurities in peptide medicines.

  2014cited by this paper
• Control Strategies for Synthetic Therapeutic Peptide APIs. Part II. Raw Material Considerations

  2014cited by this paper
• Homonuclear decoupling for enhancing resolution and sensitivity in NOE and RDC measurements of peptides and proteins.

  2014cited by this paper
• Peptide Synthesis and Applications

  2013cited by this paper
• T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation.

  2013cited by this paper
• Chemical Methods for Peptide and Protein Production

  2013cited by this paper
• Future directions for peptide therapeutics development.

  2013cited by this paper
• Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents

  2012cited by this paper
• Racemisation of N‐Fmoc phenylglycine under mild microwave‐SPPS and conventional stepwise SPPS conditions: attempts to develop strategies for overcoming this

  2012cited by this paper
• A new strategy to stabilize oxytocin in aqueous solutions: II. Suppression of cysteine-mediated intermolecular reactions by a combination of divalent metal ions and citrate.

  2012cited by this paper
• The influence of peptide impurity profiles on functional tissue-organ bath response: the 11-mer peptide INSL6[151-161] case.

  2012cited by this paper
• Qualification of FTIR spectroscopic method for protein secondary structural analysis.

  2011cited by this paper
• Understanding protein adsorption phenomena at solid surfaces.

  2011cited by this paper
• Optimized Fmoc solid‐phase synthesis of the cysteine‐rich peptide linaclotide

  2011cited by this paper
• Applications of circular dichroism (CD) for structural analysis of proteins: qualification of near- and far-UV CD for protein higher order structural analysis.

  2011cited by this paper
• “pH Swing” in Frozen Solutions—Consequence of Sequential Crystallization of Buffer Components

  2010cited by this paper
• Stability of Protein Pharmaceuticals: An Update

  2010cited by this paper
• Trace Levels of Innate Immune Response Modulating Impurities (IIRMIs) Synergize to Break Tolerance to Therapeutic Proteins

  2010cited by this paper
• The recombinant amyloid-beta peptide Abeta1-42 aggregates faster and is more neurotoxic than synthetic Abeta1-42.

  2010cited by this paper
• Shear-induced unfolding of lysozyme monitored in situ.

  2009cited by this paper
• Noninvasive continuous monitoring of solid-phase peptide synthesis by acid-base indicator.

  2009cited by this paper
• Mechanisms of protein aggregation.

  2009cited by this paper
• COMU: a safer and more effective replacement for benzotriazole-based uronium coupling reagents.

  2009cited by this paper
• Screening assay for metal-catalyzed oxidation inhibitors using liquid chromatography-mass spectrometry with an N-terminal beta-amyloid peptide.

  2009cited by this paper
• Asparagine coupling in Fmoc solid phase peptide synthesis.

  2009cited by this paper
• Development of Calcitonin Salmon Nasal Spray: similarity of peptide formulated in chlorobutanol compared to benzalkonium chloride as preservative.

  2009cited by this paper
• Examination of chiral stability during the preparation of hydrazides and coupling by the azide procedure using a series of model peptides.

  2009cited by this paper
• Towards Heat-stable Oxytocin Formulations: Analysis of Degradation Kinetics and Identification of Degradation Products

  2009cited by this paper
• Clinical significance of antibodies against calcitonin.

  2009cited by this paper
• Pharmaceutical Formulation Development Of Peptides And Proteins

  2009cited by this paper
• Reactions of C‐terminal ω‐amino acid residues in liquid hydrogen fluoride

  2009cited by this paper
• Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids.

  2009cited by this paper
• Integrating In Silico and In Vitro Analysis of Peptide Binding Affinity to HLA-Cw*0102: A Bioinformatic Approach to the Prediction of New Epitopes

  2009cited by this paper
• Oxyma: an efficient additive for peptide synthesis to replace the benzotriazole-based HOBt and HOAt with a lower risk of explosion.

  2009cited by this paper
• Current Perspectives on Stability of Protein Drug Products during Formulation, Fill and Finish Operations

  2008cited by this paper
• Identification and characterization of disulfide bonds in proteins and peptides from tandem MS data by use of the MassMatrix MS/MS search engine.

  2008cited by this paper
• Identification of Fmoc-β-Ala-OH and Fmoc-β-Ala-amino acid-OH as new impurities in Fmoc-protected amino acid derivatives*

  2008cited by this paper
• Assessment of the three-dimensional structure of recombinant protein therapeutics by NMR fingerprinting: demonstration on recombinant human granulocyte macrophage-colony stimulation factor.

  2008cited by this paper
• Impurity profiling quality control testing of synthetic peptides using liquid chromatography-photodiode array-fluorescence and liquid chromatography-electrospray ionization-mass spectrometry: the obestatin case.

  2008cited by this paper
• Problem of aspartimide formation in Fmoc‐based solid‐phase peptide synthesis using Dmab group to protect side chain of aspartic acid

  2008cited by this paper
• The impact of impurities in synthetic peptides on the outcome of T-cell stimulation assays.

  2007cited by this paper
• Accumulation of Succinimide in a Recombinant Monoclonal Antibody in Mildly Acidic Buffers Under Elevated Temperatures

  2007cited by this paper
• Fmoc-2-mercaptobenzothiazole, for the introduction of the Fmoc moiety free of side-reactions.

  2007cited by this paper
• Limiting racemization and aspartimide formation in microwave‐enhanced Fmoc solid phase peptide synthesis

  2007cited by this paper
• Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.

  2007cited by this paper
• Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization.

  2006cited by this paper
• Protein aggregation and bioprocessing

  2006cited by this paper
• Effect of N-1 and N-2 residues on peptide deamidation rate in solution and solid state

  2006cited by this paper
• Removal of peroxides in polyethylene glycols by vacuum drying: Implications in the stability of biotech and pharmaceutical formulations

  2006cited by this paper
• Pathogen recognition and development of particulate vaccines: does size matter?

  2006cited by this paper
• Effects of protein aggregates: An immunologic perspective

  2006cited by this paper
• Peptide Synthesis and Applications

  2005cited by this paper
• The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes.

  2005cited by this paper
• Chemistry of Peptide Synthesis

  2005cited by this paper
• Identification of Fmoc-beta-Ala-OH and Fmoc-beta-Ala-amino acid-OH as new impurities in Fmoc-protected amino acid derivatives.

  2005cited by this paper
• Repeated injections of PEG-PE liposomes generate anti-PEG antibodies.

  2005cited by this paper
• Aggregation of granulocyte‐colony stimulating factor in vitro involves a conformationally altered monomeric state

  2005cited by this paper
• Separation and characterization of complex crude mixtures produced in the synthesis of therapeutic peptide hormones by liquid chromatography coupled to electrospray mass spectrometry (LC–ES-MS)

  2004cited by this paper
• Racemization in stepwise solid-phase peptide synthesis at elevated temperatures

  2004cited by this paper
• Moisture-Induced Aggregation of Lyophilized Insulin

  2004cited by this paper
• Interactions of the antimicrobial beta-peptide beta-17 with phospholipid vesicles differ from membrane interactions of magainins.

  2003cited by this paper
• Micelle-Associated Protein in Epoetin Formulations: A Risk Factor for Immunogenicity?

  2003cited by this paper
• Understanding base-assisted desulfurization using a variety of disulfide-bridged peptides.

  2003cited by this paper
• Interactions of the antimicrobial β‐peptide β‐17 with phospholipid vesicles differ from membrane interactions of magainins

  2003cited by this paper
• Detection and characterization of methionine oxidation in peptides by collision-induced dissociation and electron capture dissociation

  2003cited by this paper
• Large-scale manufacture of peptide therapeutics by chemical synthesis

  2003cited by this paper
• Rapid, continuous solution-phase peptide synthesis: Application to peptides of pharmaceutical interest

  2003cited by this paper
• Bioequivalence and the immunogenicity of biopharmaceuticals

  2002cited by this paper
• Redox Properties of Met35 in Neurotoxic β-Amyloid Peptide. A Molecular Modeling Study

  2002cited by this paper
• Redox properties of Met(35) in neurotoxic beta-amyloid peptide. A molecular modeling study.

  2002cited by this paper
• Synthesis of peptides and proteins without cysteine residues by native chemical ligation combined with desulfurization.

  2001cited by this paper
• Androctonin, a hydrophilic disulphide-bridged non-haemolytic anti-microbial peptide: a plausible mode of action.

  2000cited by this paper
• Problems associated with use of the Nin-cyclohexyloxycarbonyl (Hoc) group for tryptophans

  2000cited by this paper
• Compatibility of osmolytes with Gibbs energy of stabilization of proteins.

  2000cited by this paper
• CD Spectroscopy of Proteins Adsorbed at Flat Hydrophilic Quartz and Hydrophobic Teflon Surfaces.

  2000cited by this paper
• The use of circular dichroism in the investigation of protein structure and function.

  2000cited by this paper
• The formulation of biopharmaceutical products.

  2000cited by this paper
• Sample preparation for peptide mapping--A pharmaceutical quality-control perspective.

  1999cited by this paper
• Chemical Protein Synthesis by Solid Phase Ligation of Unprotected Peptide Segments

  1999cited by this paper
• Chemical synthesis of the precursor molecule of the Aequorea green fluorescent protein, subsequent folding, and development of fluorescence.

  1998cited by this paper
• Peptide purity and counter ion determination of bradykinin by high-performance liquid chromatography and capillary electrophoresis

  1998cited by this paper
• Chemical Pathways of Peptide Degradation: IX. Metal-Catalyzed Oxidation of Histidine in Model Peptides

  1998cited by this paper
• The Effect of Benzyl Alcohol on Recombinant Human Interferon-γ

  1997cited by this paper
• Degradation pathways of salmon calcitonin in aqueous solution.

  1997cited by this paper
• Methionine residues as endogenous antioxidants in proteins.

  1996cited by this paper
• Absolute on-line molecular mass analysis of basic fibroblast growth factor and its multimers by reversed-phase liquid chromatography with multi-angle laser light scattering detection.

  1996cited by this paper
• Inhibitory effect of sugars and polyols on the metal-catalyzed oxidation of human relaxin.

  1996cited by this paper
• Oxidation of Human Insulin-Like Growth Factor I in Formulation Studies, II. Effects of Oxygen, Visible Light, and Phosphate on Methionine Oxidation in Aqueous Solution and Evaluation of Possible Mechanisms

  1996cited by this paper
• Peptide Coupling in the Presence of Highly Hindered Tertiary Amines

  1996cited by this paper
• 3-(1-Piperidinyl)alanine formation during the preparation ofC-terminal cysteine peptides with the Fmoc/t-Bu strategy

  1996cited by this paper
• Stereochemical Requirements for β-Hairpin Formation: Model Studies with Four-Residue Peptides and Depsipeptides

  1996cited by this paper
• Detection of secondary amines on solid phase.

  1995cited by this paper
• Chemical instability of protein pharmaceuticals: Mechanisms of oxidation and strategies for stabilization.

  1995cited by this paper
• Oxidation of Recombinant Human Parathyroid Hormone: Effect of Oxidized Position on the Biological Activity

  1995cited by this paper
• Chemical Pathways of Peptide Degradation. VII. Solid State Chemical Instability of an Aspartyl Residue in a Model Hexapeptide

  1994cited by this paper

• Advancement in peptide-based therapeutics for the treatment of type 2 diabetes mellitus: current progress and future prospects.

  2026cites this paper
• Web of Potentials: Neuroactive Components of Spider Venom and Their Emerging Pharmacologic Applications in Neurologic Diseases.

  2026cites this paper
• Peptide-Based Approaches for Pain Relief and Healing in Wounds

  2026cites this paper
• Regulatory Considerations in Synthetic Peptide Characterization: Techniques and Compliance

  2025cites this paper
• Proteolysis targeting chimeras (PROTACs) in oncology: a review of patents and regulatory considerations.

  2025cites this paper
• Peptide-based drugs in immunotherapy: current advances and future prospects

  2025cites this paper
• A Phase-Appropriate Risk Assessment Strategy in Support of the Safety of Peptide and Oligonucleotide-Related Impurities

  2025cites this paper
• Inhalable and Nasal Biologics: Analytical, Formulation, Development, and Regulatory Considerations

  2025cites this paper
• Protein and Peptide Therapeutics: Stability Challenges, Regulatory Demands, and Innovative Formulation Solutions for Enhanced Clinical Effectiveness.

  2025cites this paper
• Immunogenicity of therapeutic peptide products: bridging the gaps regarding the role of product-related risk factors

  2025cites this paper
• An Overview of Peptides and Peptide Pools for Antigen-Specific Stimulation in T-Cell Assays.

  2024cites this paper
• A comprehensive study on the identification and characterization of major degradation products of synthetic liraglutide using liquid chromatography‐high resolution mass spectrometry

  2024cites this paper
• Characterization of Synthetic Peptides by Mass Spectrometry.

  2024cites this paper
• Determination of related substances in disulfide-rich peptide ziconotide by establishing tandem mass spectrometry methods

  2024cites this paper
• Peptide-Hitchhiking for the Development of Nanosystems in Glioblastoma

  2024cites this paper
• Forced Degradation Products of Liraglutide: A Comparative Study of Similarity Between Originator and Analogue Version by Liquid Chromatography–Mass Spectrometry

  2024cites this paper
• Enantiomeric purity of synthetic therapeutic peptides: A review.

  2024cites this paper
• A Review on Forced Degradation Strategies to Establish the Stability of Therapeutic Peptide Formulations

  2023cites this paper
• Best Practices for Submission of NMR Data to Support Higher Order Structure Assessment of Generic Peptide Drugs

  2023cites this paper
• Evaluation of effects of temperature and humidity on the secondary structure of Ganirelix in an injectable formulation and comparison with Orgalutran® using circular dichroism spectroscopy.

  2023cites this paper
• Immunogenicity risk assessment of synthetic peptide drugs and their impurities.

  2023cites this paper
• Carbodiimide-Mediated Beckmann Rearrangement of Oxyma-B as a Side Reaction in Peptide Synthesis

  2022cites this paper
• Therapeutic Peptides: Unravelling Conformational Dynamics by Systematic Application of Biophysical Techniques.

  2022cites this paper
• Applications of Fourier Transform Infrared and UV-Visible Spectroscopy for the demonstrating sameness of Ganirelix peptide in Liquid Injection Formulation

  2022cites this paper
• Synthetic pharmaceutical peptides characterization by chromatography principles and method development.

  2022cites this paper
• Structurally related peptide impurity identification and accurate quantification for synthetic oxytocin by liquid chromatography–high-resolution mass spectrometry

  2021cites this paper
• Characterization of Synthetic Peptide Therapeutics Using Liquid Chromatography-Mass Spectrometry: Challenges, Solutions, Pitfalls, and Future Perspectives.

  2021cites this paper
• Establishment of validated stability indicating purity method based on the stress degradation behavior of gonadotropin-releasing hormone antagonist (ganirelix) in an injectable formulation using HPLC and LC-MS-QTOF

  2021cites this paper
• Determination of Amino Acid Composition of Ganirelix Acetate in an Injectable Formulation by Pre-column Derivatization with 6-Aminoquinolyl-N-hydroxysuccinimidyl Carbamate.

  2020cites this paper
• A simple, sensitive, high-resolution, customized, reverse phase ultra-high performance liquid chromatographic method for related substances of a therapeutic peptide (bivalirudin trifluoroacetate) using the quality by design approach

  2020cites this paper
• Evaluation of temperature, excipients impact on the primary structure of Ganirelix in an injectable formulation, and comparison with Orgalutran® using MALDI-TOF/TOF-MS.

  2020cites this paper
• Progress and challenges of personalized neoantigens in the clinical treatment of tumors

  2020cites this paper
• Dissolving microneedle based transdermal delivery of therapeutic peptide analogues.

  2019cites this paper
• Peptide-based therapeutics: quality specifications, regulatory considerations, and prospects.

  2019cites this paper
• Susceptibility of protein therapeutics to spontaneous chemical modifications by oxidation, cyclization, and elimination reactions

  2019cites this paper
• Water proton NMR detection of amide hydrolysis and diglycine dimerization.

  2018cites this paper
• A Comprehensive Review on Copemyl®

  2017cites this paper
• Personalized neoantigen vaccines: A new approach to cancer immunotherapy.

  2017cites this paper
• Development of Novel Transdermal Drug Delivery Technologies for Therapeutic Peptides

  2017influential citation
• Transferon™, a peptide mixture with immunomodulatory properties is not immunogenic when administered with various adjuvants

  2017cites this paper
• Impurity profiling of the synthetic peptide LL-37 using high-performance liquid chromatography with combined UV and single quadrupole mass spectrometric detection

  year unknowncites this paper